Massimo Cristofanilli
#114,177
Most Influential Person Now
Researcher
Massimo Cristofanilli's AcademicInfluence.com Rankings
Massimo Cristofanilliphilosophy Degrees
Philosophy
#4896
World Rank
#7569
Historical Rank
Logic
#2260
World Rank
#3218
Historical Rank
Download Badge
Philosophy
Massimo Cristofanilli's Degrees
- Bachelors Biology University of Milan
- Masters Biotechnology University of Milan
- PhD Molecular Biology University of Milan
Similar Degrees You Can Earn
Why Is Massimo Cristofanilli Influential?
(Suggest an Edit or Addition)Massimo Cristofanilli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Circulating tumor cells, disease progression, and survival in metastatic breast cancer. (2004) (4105)
- Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. (2008) (2455)
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (2005) (1851)
- Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System (2007) (1194)
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. (2016) (1176)
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. (2005) (1123)
- Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. (2005) (1069)
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival (2006) (969)
- Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer (2006) (751)
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (634)
- Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. (2001) (577)
- Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. (2002) (571)
- Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. (2006) (561)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (550)
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (2016) (503)
- Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer (2014) (490)
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. (2011) (439)
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer (2012) (412)
- Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. (2005) (400)
- Fingerprinting the circulating repertoire of antibodies from cancer patients (2003) (334)
- Dyadic coping in metastatic breast cancer. (2010) (325)
- Inflammatory Breast Cancer: The Disease, the Biology, the Treatment (2010) (318)
- Considerations in the development of circulating tumor cell technology for clinical use (2012) (313)
- The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. (2018) (305)
- Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings (2008) (299)
- Cancer stem cells: implications for cancer therapy. (2014) (294)
- Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. (2005) (288)
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2015) (271)
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) (262)
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer (2018) (255)
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application (2016) (226)
- Molecular mechanisms of metastasis in breast cancer—clinical applications (2010) (224)
- Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. (2003) (218)
- Breast cancer metastasis: challenges and opportunities. (2009) (213)
- Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment (2011) (210)
- Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system (2012) (207)
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer (2019) (204)
- Circulating giant macrophages as a potential biomarker of solid tumors (2014) (202)
- Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. (2010) (201)
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019) (188)
- Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. (2006) (187)
- Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. (2018) (185)
- Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer (2012) (183)
- Angiogenesis modulation in cancer research: novel clinical approaches (2002) (181)
- Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. (2007) (179)
- Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. (2008) (177)
- Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy (2005) (176)
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). (2016) (176)
- Thyroid hormone and breast carcinoma (2005) (175)
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. (2019) (172)
- Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells (2010) (167)
- The Landscape of Targeted Therapies in TNBC (2020) (157)
- A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. (2009) (155)
- Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer (2010) (155)
- Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy (2012) (150)
- Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. (2007) (148)
- Chemotherapy‐Induced Apoptosis and Bcl‐2 Levels Correlate with Breast Cancer Response to Chemotherapy (2003) (144)
- Inflammatory breast cancer (IBC) and patterns of recurrence (2007) (142)
- Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. (2009) (142)
- Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. (2018) (142)
- Nanotechnology for breast cancer therapy (2009) (142)
- Circulating tumor cells, disease progression, and survival in metastatic breast cancer. (2006) (140)
- Molecular characterization and targeted therapeutic approaches in breast cancer (2015) (140)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer (2016) (138)
- Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer (2008) (138)
- Update on the management of inflammatory breast cancer. (2003) (138)
- Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. (2011) (137)
- Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. (2006) (136)
- Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer (2017) (136)
- Circulating tumor cells in metastatic breast cancer (2008) (128)
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial (2016) (128)
- Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch® CTC test (2015) (127)
- Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets (2013) (127)
- Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. (2008) (121)
- Trends for inflammatory breast cancer: is survival improving? (2007) (120)
- Manipulating the chemokine‐chemokine receptor network to treat cancer (2007) (116)
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (116)
- CTC enumeration and characterization: moving toward personalized medicine. (2014) (113)
- Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination (2014) (112)
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer (2009) (109)
- Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. (2017) (109)
- Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early (2011) (108)
- Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. (2001) (108)
- Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer (2015) (107)
- Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials (2016) (106)
- Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer (2017) (105)
- Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. (2004) (103)
- Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. (2005) (102)
- Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. (2019) (102)
- Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells (2011) (102)
- Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer (2018) (99)
- TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients (2014) (99)
- Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. (2012) (97)
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (2017) (97)
- Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer (2017) (97)
- The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer (2005) (97)
- CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma (2005) (97)
- Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. (2008) (96)
- Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. (2011) (93)
- Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data (2009) (91)
- Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. (2011) (91)
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. (2012) (90)
- Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells (2015) (89)
- Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA (2016) (89)
- Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer (2012) (88)
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy (2018) (84)
- Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. (2010) (83)
- Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. (2003) (83)
- Molecular prognostic factors for breast cancer metastasis and survival. (2002) (83)
- HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer (2009) (82)
- CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. (2018) (80)
- Circulating tumor DNA to monitor metastatic breast cancer. (2013) (80)
- Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. (2014) (80)
- Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? (2019) (79)
- Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma (2009) (79)
- Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. (2015) (78)
- Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples (2016) (78)
- Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. (2009) (76)
- GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer (2010) (75)
- Detection of minimal residual disease in blood and bone marrow in early stage breast cancer (2010) (75)
- Inflammatory breast cancer (IBC): clues for targeted therapies (2013) (74)
- International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). (2011) (74)
- Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment (2004) (74)
- Paclitaxel in the multimodality treatment for inflammatory breast carcinoma (2001) (73)
- Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome (2003) (72)
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer (2018) (72)
- International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference (2018) (71)
- Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer (2016) (71)
- Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells (2010) (71)
- Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. (2010) (69)
- Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). (2020) (68)
- Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome (2011) (67)
- Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases (2018) (66)
- CXCR4 expression in early breast cancer and risk of distant recurrence. (2009) (66)
- 18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer (2010) (65)
- Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer (2016) (65)
- Disease‐free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy (2006) (64)
- Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. (2011) (64)
- Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner (2016) (64)
- Circulating tumor cells in breast cancer: Advanced tools for “tailored” therapy? (2006) (64)
- Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. (2002) (63)
- Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation (2012) (63)
- β4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer (2005) (63)
- Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. (2018) (62)
- Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells (2017) (62)
- Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations (2015) (62)
- Reply to differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population‐based study (2011) (62)
- Imaging and Analysis of 3D Tumor Spheroids Enriched for a Cancer Stem Cell Phenotype (2010) (61)
- Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer (2017) (60)
- Prognostic significance of HER‐2 status in women with inflammatory breast cancer (2008) (60)
- Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer (2011) (60)
- MRI features of inflammatory breast cancer. (2011) (60)
- Combined‐modality treatment for isolated recurrences of breast carcinoma (2005) (59)
- Survival of women with inflammatory breast cancer: a large population-based study. (2014) (59)
- Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. (2008) (59)
- p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer (2004) (58)
- Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells (2012) (58)
- Circulating tumor cells in breast cancer: A tool whose time has come of age (2011) (57)
- Defining the clinical diagnosis of inflammatory breast cancer. (2008) (55)
- Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer (2008) (55)
- GSK-3 inhibition overcomes chemoresistance in human breast cancer. (2016) (54)
- Molecular targets for treatment of inflammatory breast cancer (2009) (54)
- Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer (2018) (54)
- Inflammatory breast cancer: what progress have we made? (2011) (54)
- A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer (2012) (54)
- Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions (2016) (53)
- Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer (2012) (53)
- CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. (2014) (53)
- Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. (2013) (53)
- CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer (2016) (52)
- Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors (2010) (52)
- Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4 (2010) (51)
- Identifying factors that impact survival among women with inflammatory breast cancer. (2012) (51)
- Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. (2015) (51)
- Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy (2005) (51)
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. (2018) (50)
- Circulating tumor cells revisited. (2010) (49)
- Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients (2009) (49)
- Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. (2010) (49)
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (2018) (48)
- A nonreplicating adenoviral vector that contains the wild‐type p53 transgene combined with chemotherapy for primary breast cancer (2006) (48)
- Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. (2000) (47)
- Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. (2014) (47)
- Nipple aspirate fluid cytology in breast carcinoma (2002) (47)
- Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors. (2008) (46)
- Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. (2019) (46)
- Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy (2004) (46)
- Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy (2007) (46)
- Predictors of systemic recurrence and disease‐specific survival after ipsilateral breast tumor recurrence (2005) (46)
- Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer (2010) (46)
- Circulating tumor cells in newly diagnosed inflammatory breast cancer (2015) (46)
- Presence of anaplastic lymphoma kinase in inflammatory breast cancer (2013) (45)
- Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. (2018) (45)
- ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer (2021) (45)
- Genomic and expression analysis of microdissected inflammatory breast cancer (2013) (44)
- Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors (2016) (44)
- Circulating Tumor Cells With Epithelial–to–mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer (2019) (44)
- International liquid biopsy standardization alliance white paper. (2020) (44)
- The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer (2017) (44)
- Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer (2016) (43)
- A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2008) (42)
- Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice (2021) (42)
- Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. (2013) (42)
- Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer (2016) (41)
- Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer (2002) (41)
- Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients (2017) (41)
- Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy (2008) (40)
- Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients (2013) (40)
- Phase II study of adozelesin in untreated metastatic breast cancer (1998) (40)
- The medical treatment of inflammatory breast cancer. (2008) (40)
- Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow (2009) (39)
- Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer (2020) (38)
- A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. (2013) (38)
- Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. (2017) (38)
- Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase‐Plasminogen‐Activator System in Early Breast Cancer Patients (2015) (38)
- Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. (2005) (38)
- Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. (2020) (38)
- Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells (2015) (37)
- Circulating tumor cells as prognostic marker in metastatic breast cancer (2010) (37)
- Inflammatory breast carcinoma: the sphinx of breast cancer research. (2004) (37)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer (2020) (36)
- Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer (2019) (36)
- EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells (2013) (36)
- Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients (2011) (36)
- The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. (2013) (36)
- Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. (2013) (35)
- Expression of c‐kit Proto‐Oncogene Product in Breast Tissue (2004) (35)
- Prospective changes in global DNA methylation and cancer incidence and mortality (2016) (34)
- High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. (2003) (34)
- A novel strategy to block mitotic progression for targeted therapy (2019) (34)
- New generation of molecular prognostic and predictive tests for breast cancer. (2007) (34)
- Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer (2010) (34)
- MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer (2016) (33)
- Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas (2016) (33)
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
- Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer (2019) (33)
- What progress have we made in managing inflammatory breast cancer? (2007) (32)
- The biological information obtainable from circulating tumor cells. (2009) (32)
- Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model (2018) (32)
- Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? (2013) (31)
- PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (2015) (31)
- Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer (2014) (30)
- Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. (2020) (29)
- Inflammatory breast cancer. (2009) (29)
- Landscape of circulating tumour DNA in metastatic breast cancer (2020) (29)
- Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology (2021) (29)
- Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib (2018) (29)
- Circulating tumor cells in metastatic inflammatory breast cancer. (2009) (28)
- Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. (2019) (28)
- CTCs in metastatic breast cancer. (2012) (28)
- Suberoylanilide hydroxamic acid blocks self‐renewal and homotypic aggregation of inflammatory breast cancer spheroids (2010) (28)
- Prognostic value of initial clinical disease stage after achieving pathological complete response. (2008) (28)
- Oncological care organisation during COVID-19 outbreak (2020) (28)
- Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients (2016) (27)
- Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy (2015) (27)
- Incidence of and survival following brain metastases among women with inflammatory breast cancer. (2010) (27)
- Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors (2020) (27)
- Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer (2016) (27)
- Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. (2012) (26)
- Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome (2010) (26)
- Genomic Profiling of Pre-Clinical Models of Inflammatory Breast Cancer Identifies a Signature of Epithelial Plasticity and Suppression of TGFò Signaling (2012) (26)
- Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer (2017) (26)
- A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone (2016) (26)
- Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. (2016) (26)
- Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. (2006) (26)
- Circulating tumor cells in breast cancer: fiction or reality? (2008) (25)
- Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer (2019) (25)
- Circulating Tumor Cells in Patients With Breast Cancer Dormancy (2005) (25)
- Integrating Circulating Tumor Cell Assays into the Management of Breast Cancer (2007) (25)
- Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes (2016) (25)
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. (2012) (25)
- A gene signature in breast cancer. (2007) (25)
- Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinoma (2004) (24)
- The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. (2020) (24)
- AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models (2014) (24)
- Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). (2016) (24)
- Breast Cancer Stem Cell Isolation. (2016) (24)
- A Phase II study of intravenous exatecan mesylate (DX‐8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma (2003) (23)
- Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics (2021) (23)
- Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. (2017) (23)
- Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). (2017) (23)
- Dielectric cell separation of fine needle aspirates from tumor xenografts. (2008) (23)
- The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy (2012) (23)
- Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. (2020) (22)
- Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. (2018) (22)
- A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer (2012) (21)
- Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow (2011) (21)
- Recurrent granulomatous mastitis mimicking inflammatory breast cancer (2011) (21)
- Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma (2013) (20)
- Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial (2018) (20)
- Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. (2014) (20)
- Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. (2006) (20)
- Developmental therapeutics for inflammatory breast cancer: Biology and translational directions (2016) (20)
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. (2017) (19)
- Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents (2020) (19)
- Genomic of circulating tumor cells in metastatic breast cancer (2007) (19)
- Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors (2020) (19)
- Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups (2015) (19)
- Circulating tumour cells: telling the truth about metastasis. (2014) (19)
- Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. (2022) (19)
- NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers (2019) (19)
- The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells (2016) (18)
- Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics. (2017) (18)
- Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. (1999) (18)
- Surfaced-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) Differentiation of Serum Protein Profiles of BRCA-1 and Sporadic Breast Cancer (2005) (18)
- Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). (2019) (18)
- A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy (2019) (18)
- Current state of clinical trials in breast cancer brain metastases. (2019) (18)
- Primary Peritoneal Serous Carcinoma Presenting as Inflammatory Breast Cancer (2009) (18)
- Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer (2021) (18)
- Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies (2020) (18)
- Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). (2013) (18)
- Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT (2009) (17)
- A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process (2015) (17)
- Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer (2018) (17)
- Systemic treatments for inflammatory breast cancer. (2005) (17)
- Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone (2012) (17)
- Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? (2017) (17)
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. (2018) (16)
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
- Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. (2010) (16)
- Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables (2014) (16)
- EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer (2021) (16)
- Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 (2017) (15)
- The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. (2006) (15)
- New horizons in treating metastatic disease. (2001) (15)
- Is Personalized Medicine Here? (2016) (15)
- Molecular targets in breast cancer: current status and future directions. (2002) (15)
- 1–21 Isolated Tumor Cells in Bone Marrow Three Years After Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome (2005) (15)
- Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers (2016) (15)
- Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up (2021) (15)
- Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens (2004) (14)
- Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection (2021) (14)
- Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. (2018) (14)
- Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). (2011) (14)
- Novel targeted therapies in inflammatory breast cancer (2010) (14)
- Circulating Tumor Cells and PET (2011) (14)
- Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. (2017) (14)
- The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives (2021) (13)
- The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. (2008) (13)
- Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference (2017) (13)
- Endocrine resistance in breast cancer: what really matters? (2007) (13)
- A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. (2003) (13)
- Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2009) (13)
- Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results. (2021) (13)
- Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials (2020) (13)
- Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. (2016) (13)
- The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer (2020) (13)
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology (2019) (12)
- Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer (2017) (12)
- The Third International Inflammatory Breast Cancer Conference (2013) (12)
- Inflammatory breast cancer. (2011) (12)
- Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis (2005) (12)
- Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer (2005) (12)
- Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium (2019) (12)
- Circulating Tumor Cells (CTCs) and Epithelial Mesenchymal Transition (EMT) in Breast Cancer: Describing the Heterogeneity of Microscopic Disease. (2009) (12)
- Weekly high-dose paclitaxel(HD-P) has significant antitumor activity in inflammatory breast cancer (IBC) (2001) (12)
- Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC) (2005) (12)
- Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. (2019) (12)
- Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. (2018) (11)
- Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer (2019) (11)
- Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’? (2022) (11)
- Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3 (2021) (11)
- Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer (2021) (11)
- Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior (2022) (11)
- Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. (2009) (11)
- A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. (2013) (11)
- Aldehyde Dehydrogenase1 Immunohistochemical Staining in Primary Breast Cancer Cells Independently Predicted Overall Survival But Did Not Correlate with the Presence of Circulating or Disseminated Tumors Cells (2014) (11)
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. (2016) (11)
- The “microscopic” revolution in breast carcinoma (2005) (10)
- Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. (2005) (10)
- Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC). (2017) (10)
- Emerging Role of Genomics and Cell-Free DNA in Breast Cancer (2019) (10)
- Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 (2021) (10)
- Experience with 9-Cis Retinoic Acid in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma (2000) (10)
- Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer (2010) (10)
- Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. (2010) (10)
- TP 53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients (2017) (10)
- Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
- Abstract P5-10-02: Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC) (2010) (9)
- Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. (2016) (9)
- Abstract OT2-6-03: A single arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery (2013) (9)
- Characterization of Metastatic Breast Cancer Patients with Non-Detectable Circulating Tumor Cells. (2009) (9)
- Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer (2021) (8)
- Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer (2018) (8)
- New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy (2020) (8)
- Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice (2020) (8)
- Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer (2020) (8)
- Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial. (2019) (8)
- Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis (2012) (8)
- Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience (1999) (8)
- Immune phenotype of patients with stage IV metastatic inflammatory breast cancer (2020) (8)
- Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications (2018) (8)
- NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity (2018) (8)
- Serum HER2 levels determined by two methods in patients with metastatic breast cancer (2012) (7)
- Inflammatory Breast Cancer: An Update (2012) (7)
- Serum EGFR and Serum HER-2/neu Are Useful Predictive and Prognostic Markers in Metastatic Breast Cancer Patients Treated With Metronomic Chemotherapy (2008) (7)
- Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer (2021) (7)
- PD03-01: An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC. (2011) (7)
- Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. (2022) (7)
- Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series (2011) (7)
- Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer (2021) (7)
- Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. (2004) (7)
- Erratum: A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer (J Surg Res (2009) 155 (231)) (2010) (7)
- 3-7 Inflammatory Breast Cancer Outcome With Epirubicin-Based Induction and Maintenance Chemotherapy: Ten-Year Results From the French Adjuvant Study Group GETIS 02 Trial (2007) (7)
- Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. (2010) (6)
- Toxicity profile of approved anti-PD1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials. (2016) (6)
- Proceedings of the First International Inflammatory Breast Cancer Conference (2010) (6)
- Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer (2006) (6)
- Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer (2019) (6)
- 4–4 Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity (2006) (6)
- IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. (2015) (6)
- Circulating tumor cells - not serum tumor markers - predict survival in metastatic breast cancer (2005) (6)
- Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer. (2011) (6)
- Emerging Innovative Therapeutic Approaches Leveraging Cyclin‐Dependent Kinase Inhibitors to Treat Advanced Breast Cancer (2018) (6)
- A global approach to inflammatory breast cancer. (2011) (6)
- LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology (2020) (6)
- Patient‐centered engagement and symptom/toxicity monitoring in the new era of tumor next‐generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms (2019) (6)
- Circulating tumor cells versus imaging : Predicting overall survival in metastatic breast cancer. Commentary (2006) (6)
- Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy (2018) (6)
- To the editor [8] (2007) (5)
- CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome (2022) (5)
- Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies. (2017) (5)
- The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. (2010) (5)
- Segal and Dowsett , p . 1724 Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor – Positive Breast Cancer (2014) (5)
- Inflammatory breast cancer: a new approach. (2016) (5)
- Postive sentinel nodes after neoadjuvant chemotherapy: What factors predict additional disease in the axilla? (2006) (5)
- Abstract PD4-04: Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies (2020) (5)
- High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy (2006) (5)
- Comparison of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaTest breast cancer for detection and biological characterization (2008) (5)
- A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis. (2017) (5)
- Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria. (2004) (5)
- Abstract 1597: Increased circulating tumor cell (CTC) after systemic therapy is associated with younger age in stage III/IV breast cancer patients (2018) (4)
- Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]. (2020) (4)
- Protein Pathway Activation Mapping for Multi-Omic Based Precision Medicine (2016) (4)
- Phase II study of weekly docetaxel (Taxotere; txt) and trastuzumab (Herceptin; H) for patients with HER-2 overexpressing (HER2+) metastatic breast cancer (MBC) (2001) (4)
- Phase I open-labeled trial of gemcitabine and dasatinib in advanced solid tumors (2008) (4)
- Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance. (2020) (4)
- A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System (2022) (4)
- Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer (2022) (4)
- Inflammatory breast cancer: defining a new entity. (2008) (4)
- Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy (2013) (4)
- Survival of patients with breast cancer tumors 1 cm or less. Analysis of the Surveillance, Epidemiology and End Results (SEER) Registry (2005) (4)
- New Treatment Strategies for the Inflammatory Breast Cancer (2021) (4)
- A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). (2012) (4)
- Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer (2021) (4)
- Abstract 3798: Multiplex phenotyping of circulating cancer associated macrophage-like cells in patients with solid tumors (2017) (4)
- PARP Inhibitors for Chemoprevention—Letter (2014) (4)
- Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. (2004) (4)
- P4-03-06: Development and Comparative Characterization of Metastasis in Newly Developed Pre-Clinical Models of Inflammatory Breast Cancer. (2011) (4)
- Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients (2020) (4)
- Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC). (2014) (4)
- Long-term Follow-up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy (2005) (4)
- Abstract P6-03-01: A phase Ib study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer – First analysis (2015) (4)
- Abstract OT2-3-01: Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC) (2012) (4)
- The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent). (2018) (4)
- Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer. (2009) (4)
- Detecting and Monitoring Circulating Stromal Cells from Solid Tumors Using Blood-Based Biopsies in the Twenty-First Century: Have Circulating Stromal Cells Come of Age? (2017) (3)
- Abstract C22: A phase Ib study of the CXCR1/2 inhibitor Reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer - final analysis (2015) (3)
- Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies. (2015) (3)
- Predictive Value of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer Patients Treated by Bevacizumab-Based Therapy. (2009) (3)
- Abstract PD4-05: Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors (2018) (3)
- Machine learning-assisted elucidation of CD81–CD44 interactions in promoting cancer stemness and extracellular vesicle integrity (2022) (3)
- Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer (2016) (3)
- Cristofanilli M, Hayes DF, Budd GT et al.Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-30 (2005) (3)
- Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype (2019) (3)
- Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC (2022) (3)
- Genomic and Proteomic Pathway Mapping Reveals Signatures of Mesenchymal-Epithelial Plasticity in Inflammatory Breast Cancer (2011) (3)
- Abstract P1-17-01: Differences in Survival among Women with Stage III Inflammatory and Non-Inflammatory Locally Advanced Breast Cancer Appear Early: A Large Population Based Study (2010) (3)
- Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3. (2017) (3)
- A Progress Review of the Inflammatory Breast Cancer Registry at the University of Texas M.D. Anderson Cancer Center. (2009) (3)
- Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. (2021) (3)
- Disseminated tumor cells in primary breast cancer: Evaluation of the percentage of breast cancer stem cells in bone marrow aspirates of patients receiving neoadjuvant chemotherapy. (2009) (3)
- Breast Cancer in the Asian Indian Population of the United States: A Call for Screening and Education (2008) (3)
- Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial. (2017) (3)
- Abstract P3-05-01: Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups (2012) (3)
- Soluble Factors and Circulating Tumor Cells in Inflammatory Breast Cancer. (2009) (3)
- Breast cancer in low-income countries: India as a model. (2014) (2)
- Applying a mitotic index to circulating tumor cells and its prognostic significance: A cytological approach to patient stratification. (2015) (2)
- Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis (2021) (2)
- Abstract 408: Expression of CCR5 associated with HER2 in circulating tumor cells (CTCs) is a novel biomarker for patients with metastatic breast cancer (MBC) (2019) (2)
- Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma (2002) (2)
- Abstract P6-14-06: CCR5 antagonists suppresses the migration and invasion of human inflammatory breast cancer cells (2015) (2)
- Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies. (2018) (2)
- Brain metastasis in breast cancer: last barrier to the cure? (2012) (2)
- Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies? (2015) (2)
- The pan-HDAC Inhibitor Suberoylanilide Hydroxamic Acid Targets Self Renewal of Breast Cancer Stem Cells. (2009) (2)
- Limited efficacy and significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts). (2012) (2)
- Liquid Biopsies in Solid Tumors (2017) (2)
- Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies (2017) (2)
- Cxcr4 expression and risk of bone metastasis in patients with early breast cancer (2007) (2)
- Abstract S3-06: Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer (2013) (2)
- The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study (2015) (2)
- Seasonal Variation in Inflammatory Breast Cancer (2016) (2)
- Abstract P4-01-04: Circulating tumor cells (CTC) are associated with defects in innate and adaptive immunity in inflammatory breast cancer (IBC) patients (2015) (2)
- In reply [2] (2005) (2)
- Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (2016) (2)
- Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. (2009) (2)
- Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3). (2019) (2)
- Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. (2022) (2)
- Persistence of Bone Marrow Micrometastases in Patients Receiving Adjuvant Therapy for Breast Cancer: Results at 4 Years (2005) (2)
- Metastatic breast cancer: focus on endocrine sensitivity (2016) (2)
- Synergistic Effect of Lapatinib and the Class 1 HDAC Inhibitor SNDX-275 in Breast Cancer. (2009) (2)
- Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. (2018) (2)
- Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies. (2018) (2)
- A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC). (2019) (2)
- Palbociclib and Fulvestrant in Breast Cancer. Reply. (2019) (2)
- EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells (2013) (2)
- Abstract P2-11-23: MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping (2013) (2)
- Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer (2021) (2)
- Abstract 5342: FC-IBC-02: A newin vitro-in vivomodel of inflammatory breast cancer (IBC) (2012) (2)
- Abstract P1-16-01: Efficacy of endocrine- versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA) (2019) (2)
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer (2023) (2)
- Abstract P4-13-18: A phase I study of romidepsin in combination with nab-paclitaxel in patients with metastatic HER-2 negative inflammatory breast cancer (IBC) (2016) (2)
- CCR5 governs DNA damage and breast cancer stem cell expansion (2017) (2)
- Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation (2022) (2)
- Lymphomagenesis in Circulating Tumor Cell-Derived Xenograft Models (2019) (2)
- Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer. (2013) (2)
- Leptomeningeal metastases: the future is now (2022) (2)
- Inflammatory Breast Cancer: A Complex Disease (2008) (2)
- Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIVaggressive breast cancer. (2021) (2)
- Time for a shift in molecular down staging in luminal breast cancer. (2019) (2)
- Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (2)
- Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity (2023) (2)
- CirculatingTumor Cells versus ImagingPredicting Overall Survival in Metastatic Breast Cancer (2006) (2)
- Abstract PD04-02: Clinical Value of Circulating Tumor Cells (CTC) in First Line Metastatic Breast Cancer (MBC) Patients (pts) According to Type of Treatment and Immunohistochemical Molecular Subtype (2010) (2)
- New Therapeutic Targets in Inflammatory Breast Cancer (2012) (2)
- Detection of Predictive Biomarkers Using Liquid Biopsies (2018) (2)
- Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. (2017) (2)
- Abstract P2-02-14: Detection and characterization of CTCs isolated by ScreenCell®-Filtration in metastatic breast cancer (2016) (2)
- Abstract P5-13-06: Seasonal variation in onset of inflammatory breast cancer: Evidence of an infectious trigger (2013) (2)
- Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC). (2016) (2)
- Concordance of mutations identified using circulating tumor DNA (ctDNA) compared to tissue based next generation sequencing (NGS) in gastrointestinal malignancies: A single institution experience. (2017) (2)
- Inflammatory breast cancer: defining breast magnetic resonance imaging features. (2009) (2)
- Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response. (2020) (1)
- A phase II trial of PS-341 in metastatic breast cancer (MBC) (2004) (1)
- Abstract PD05-03: What is the appropriate sample (s) on which to perform sequencing for mutational analysis to guide the selection of targeted therapy? (2012) (1)
- Abstract P2-02-11: Detection of activating estrogen receptor 1 (ESR1) mutation on single circulating tumor cells from metastatic breast cancer patients (2016) (1)
- Molecular Medicine in Practice Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer (2012) (1)
- Populations of cells exhibiting epithelial-mesenchymal transition (EMT) or stem cell characteristics can be propagated from a single inflammatory breast cancer (IBC) cell line based on culture conditions. (2009) (1)
- Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools? (2021) (1)
- Circulating tumor cells and FDG-PET/CT: biological and functional methods for therapeutic monitoring in metastatic breast cancer. (2009) (1)
- Abstract 5589: T-cell cytokine production profile of breast cancer patients (2010) (1)
- Abstract P5-13-04: NF1 mutations render HER2+ breast cancer highly sensitive to T-DM1 by altering microtubule dynamics (2022) (1)
- Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC) (2014) (1)
- Abstract 1448: Identifying and subtyping circulating tumor cells from breast, prostate, and pancreatic cancer patients based on distinct morphology. (2013) (1)
- Abstract 5583: Innate immune profile of inflammatory breast cancer patients (2010) (1)
- Circulating Tumor Cells: Toward Sophisticated Approaches in Managing Metastatic Breast Cancer (2008) (1)
- Abstract 5165: Cancer associated macrophage-like cells as a blood-based biomarker for the screening of solid tumors (2015) (1)
- 310PPREVENTIVE TAMOXIFEN AFTER DUCTAL CARCINOMA IN SITU (DCIS) DIAGNOSIS ACCORDING TO AGE AND ETHNICITY. (2014) (1)
- Current methods to prevent the development of breast cancer. (1998) (1)
- Immune Profile of Inflammatory Breast Cancer Patients. (2009) (1)
- Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers (2022) (1)
- Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer (2022) (1)
- Considerations in the development of circulating tumor cell technology for clinical use (2012) (1)
- Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue? (2020) (1)
- Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics (2021) (1)
- Helping Patients with Breast Cancer Decide about Clinical Trials Participation (2016) (1)
- Abstract P5-01-08: Landscape of circulating tumor DNA (ctDNA) in metastatic breast cancer (2020) (1)
- Blood-Based Diagnostics in Solid Tumors: An Overview (2017) (1)
- Abstract P2-04-02: Identifying molecular targets and mechanisms of treatment resistance in inflammatory breast cancer (IBC) using reverse-phase protein microarrays (RPMA) (2015) (1)
- Outcomes in Young Women With Breast Cancer of Triple-Negative Phenotype: The Prognostic Significance of CK19 Expression (2009) (1)
- Abstract P6-12-07: Prevalence of propionibacterium acnes and bartonella henselae DNA in patients with inflammatory breast cancer (IBC) (2013) (1)
- Prognostic and Predictive Role of Circulating Tumor Cells (2019) (1)
- The role of magnetic resonance imaging as an imaging tool to assess disease status and residual disease in locally advanced breast cancer (2005) (1)
- CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response (2022) (1)
- Abstract PD05-01: Next generation genomic sequencing (NGS) identifies molecular targets in inflammatory breast cancer (IBC) (2012) (1)
- Abstract OT1-03-07: A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for triple-negative breast cancer (fRida) (2016) (1)
- Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. (2018) (1)
- Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3 (2020) (1)
- Abstract 5195: Increased circulating tumor cell (CTC) clusters are associated with significantly higher levels of HER2 expression and metastasis in stage III/IV breast cancer (2018) (1)
- Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. (2018) (1)
- Circulating tumor cells (CTCs) in metastatic breast cancer: Biological value beyond tumor burden. (2006) (1)
- Abstract 4593: Genomic profiling of cell free DNA (cfDNA) from patients with inflammatory breast cancer (IBC) (2018) (1)
- 380 A novel skin assessment tool for inflammatory breast cancer (IBC) (2010) (1)
- Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis (2020) (1)
- Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer. (2009) (1)
- A phase II trial of PS-341 in metastatic breast cancer (MBC). (2004) (1)
- A multigene assay for predicting the recurrence of tamoxifen-treated, node-negative breast cancer (2005) (1)
- Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy (2014) (1)
- Abstract P2-01-01: Establishment and validation of circulating tumor cell-based prognostic nomograms in 497 first-line metastatic breast cancer patients (2012) (1)
- Abstract 3887: Genomic analysis identifies drug targetable pathways and predicts immune infiltration in inflammatory breast cancer tumors (2015) (1)
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib (2022) (1)
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer (2018) (1)
- Circulating tumor cells and novel biomarkers for prognostic and biological of breast cancer (2005) (1)
- Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data (2021) (1)
- Abstract P6-18-03: Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies (2019) (1)
- Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies. (2021) (1)
- Identifying and Subtyping Circulating Tumor Cells (CTCs) from breast, prostate and pancreatic cancer patients based on distinct morphology (2013) (1)
- 2001 : Long-Term Local-Regional Treatment Outcomes for Patients With Inflammatory Breast Cancer (2006) (1)
- The pattern of chemokine receptors expressed by tumor cells predicts the site of metastatic relapse in patients with axillary node positive breast cancer (2005) (1)
- Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner (2016) (1)
- Abstract P3-01-08: HER2-negative metastatic breast cancer with HER2-positive circulating tumor cells (CTCs): A new CTC-defined HER2-positive subgroup (2019) (1)
- Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials (2016) (1)
- Increased expression of chemokine receptors in inflammatory breast cancer: Implications for novel targeted therapies (2005) (1)
- Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients. (2012) (1)
- Effect of targeted therapy on circulating tumor cells in patients with metastatic breast cancer. (2012) (1)
- Abstract P3-10-03:Bartonella henselaeInfection Detected in Patients with Inflammatory Breast Cancer. (2012) (1)
- Tumor and Stem Cell Biology CCR 5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene – Transformed Metastatic Prostate Cancer Cell Lines (2014) (1)
- Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety (2016) (1)
- 169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis (2022) (1)
- Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China. (2020) (1)
- Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer (2012) (1)
- Dissemination of Circulating Tumor Cell Clusters Occurs Early in Non‑metastatic Breast Cancer Patients (2021) (1)
- Abstract P2-04-03: Circulating tumor DNA (ctDNA) provides molecular monitoring for inflammatory breast cancer (IBC) (2015) (1)
- Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS). (2021) (1)
- Inflammatory breast cancer: Current imaging perspectives (2001) (1)
- Abstract P4-01-04: ESR1 mutation in cell free DNA (cfDNA) is associated with significantly increased circulating tumor cell (CTC)-clusters and progress in stage III/IV breast cancer after systemic treatments (2019) (1)
- Abstract PD8-07: Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer (2021) (1)
- Abstract P4-10-15:PIK3CAmutational analysis using cell-free DNA next-generation sequencing detects activating mutations that may be missed with targeted hot-spot testing (2020) (1)
- Abstract 2631: Cancer associated macrophage-like (CAMLs) cells in blood predict progression and survival for all stages of solid tumors (2018) (1)
- Application of next-generation sequencing (NGS) for evaluation of advanced epithelial cancers: A single institution experience. (2013) (1)
- The Third International Inflammatory Breast Cancer Conference (2013) (1)
- A pilot study detailing cancer-specific biomarkers in giant macrophages mimicking circulating tumor cells in the circulation of cancer patients. (2014) (1)
- Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination (2014) (1)
- Abstract P3-02-03: Prognostic Value of Circulating Tumor Cells (CTC) in HER-2 Positive Metastatic Breast Cancer (MBC) Patients (pts) Treated with Anti-HER2-Based Therapy (2010) (1)
- Abstract LB-370: A novelex vivoculture workflow to enrich and expand circulating tumor cells (CTCs) from patients with stage III/IV breast cancer (BCa) (2018) (1)
- Abstract P2-02-21: The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity (2018) (0)
- Molecular characterization and targeted therapeutic approaches in breast cancer (2015) (0)
- Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer (2022) (0)
- Weekly T rastuzumab a nd P aclitaxel T herapy f or M etastatic Breast C ancer W ith A nalysis o f E fficacy b y HER2 Immunophenotype a nd G ene A mplification (2001) (0)
- CTCs and Circulating Tumor DNA for the Monitoring of Breast Cancer Patients (2017) (0)
- Gene Signatures of Inflammatory Breast Cancer: Epithelial Plasticity and a Cancer Stem Cell Phenotype (2013) (0)
- Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients (2015) (0)
- Abstract GS1-05: HotspotESR1mutations rewire cell-cell adhesome to facilitate breast cancer metastasis (2021) (0)
- Introduction: Why IBC Now? (2012) (0)
- Metastatic Breast Cancer - Opportunities from Novel Diagnostic Modalities (2005) (0)
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer (2019) (0)
- Abstract P1-14-05: Predicting Brain Metastasis in Breast Cancer Patients: Who Is at Highest Risk? (2010) (0)
- Keeping oncologists current with CDK4/6 inhibitors in HR+ breast cancer: The impact of online education. (2020) (0)
- 103 The use of next generation sequencing (NGS) in the management of metastatic breast cancer (MBC): Defining a model for genomic-driven therapies (2014) (0)
- Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients. (2011) (0)
- Abstract P2-10-32: Sialyl LewisXand inflammatory mediators in breast cancer patients: biological correlations and prognostic value (2012) (0)
- Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies (2018) (0)
- Evidence for the use of circulating tumor cells in the prognostic stratification of women with metastatic breast cancer (2009) (0)
- Clinical Outcomes in Two Different Cohorts of Patients with Inflammatory Breast Cancer (IBC) Treated at the MD Anderson Cancer Center: The Experience of the Morgan Welch IBC Research Program and Clinic. (2009) (0)
- Abstract P5-06-27: Circulating cancer associated macrophage-like cells (CAMLs) are early predictors of response to new line therapies in metastatic breast cancer (2020) (0)
- Abstract PD8-03: Clinico-pathological and molecular features in young women with metastatic breast cancer (2020) (0)
- Abstract P4-01-18: Correlation between circulating tumor DNA (ctDNA) alterations and circulating tumor cells (CTC) uncovers new mechanisms of metastasis for patients with metastatic breast carcinoma (MBC) (2019) (0)
- Abstract PS2-05: Genetic profiling for circulating tumor cell clusters to unveil molecular drivers of metastasis (2021) (0)
- Abstract P1-01-05: Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAML) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process (2017) (0)
- Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis (2023) (0)
- Real-time monitoring of circulating stromal cells in the blood to predict responsiveness of new-line therapies in metastatic breast cancer. (2019) (0)
- B07 Mechanisms of Alectinib Resistance in a Leptomeningeal Carcinomatosis of EML4-ALK Lung Cancer and Its Circumvention by EGR-TKIs (0)
- Elevated serum levels of Sialyl Lewis X (sLeX) and inflammatory cytokines in patients with nonmetastatic breast cancer. (2011) (0)
- Predictors of Persistent Micrometastatic Disease after Neoadjuvant Chemotherapy. (2009) (0)
- Abstract 2636: Targeted therapies to ERBB receptors downregulate expression of PD-L1: implications in combination therapies (2017) (0)
- Abstract P3-02-08: Detection of Circulating Tumor Cells Prior to Autologous Stem Cell Transplantation Is Predictive of Shorter Progression Free Survival in Metastatic Breast Cancer (2010) (0)
- Circulating Tumor Cells in Aggressive Breast Cancer (2004) (0)
- Abstract P5-06-01: A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System in support of FDA clearance (2023) (0)
- Abstract A19: CCR5 contributes to breast cancer stem cell expansion by enhancing DNA damage repair (2016) (0)
- Abstract P1-05-06: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC) (2017) (0)
- Abstract P2-02-06: Her2-low ctcs in breast cancer: Pipeline for phenotypic driven, single-cell collection and molecular analysis (2022) (0)
- Inflammatory Breast Cancer : A Complex Disease December (2017) (0)
- P4-20-04: Cytokine Synthesis by Activated Dendritic Cells in Relation to Disease Progression in Inflammatory Breast Cancer (IBC). (2011) (0)
- Abstract 1388: Multi-template analysis in metastatic breast cancer blood samples (2016) (0)
- Concordance of genomic alterations by next generation sequencing (NGS) in tumor tissue vs. cell-free DNA in advanced breast cancer. (2016) (0)
- Abstract P2-08-09: Prognostic values of circulating tumor cell (CTC) enumeration and their clusters in advanced breast cancer (2016) (0)
- Hyper engorged cancer associated macrophage-like cells in circulation predict for multi-organ metastatic disease in solid tumors. (2021) (0)
- Herceptin Plus Chemotherapy Combination in Preoperative Regimen May Offer Clinical Benefit in Early Stage Breast Cancer (2005) (0)
- Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary. (2023) (0)
- Abstract PS2-06: The detection and enumeration of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in metastatic breast cancer (2021) (0)
- Impact of Triple Negative Phenotype on Breast Cancer Prognosis: Kaplan HG, Malmgren JA (Swedish Cancer Inst at Swedish Med Ctr, Seattle, WA; HealthStat Consulting Inc, El Segundo, CA) Breast J 14:456-463, 2008 § (2009) (0)
- Isolation and Identification of Circulating Tumor Cells (CTCs) from breast and prostate cancer patients (2014) (0)
- MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer (2022) (0)
- P4-07-10: Circulating Tumor Cells in Newly Diagnosed Inflammatory Breast Cancer. (2011) (0)
- Abstract #4790: Subsets of Mesenchymal Stem Cells Correlate With Breast Cancer-Propagating Cells in Bone Marrow (2009) (0)
- Abstract P5-05-04: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study (2023) (0)
- Abstract 1046: Developing patient-derived xenograft tumor models that recapture clinical manifestation of inflammatory breast cancer patients (2018) (0)
- Abstract P1-16-08: Response to subsequent therapy after dual immune checkpoint blockade in metastatic breast cancer (2019) (0)
- Immunophenotypic analysis of inflammatory breast cancers: Identification of an 'inflammatory signature' (2005) (0)
- CTC in Advanced Breast Cancer Prognosis, Monitoring, and Clinical Utility (2016) (0)
- Abstract P1-24-02: Genetic variants and tumor microenvironment in inflammatory breast cancer: Clues for targeted therapies (2022) (0)
- Abstract P6-03-01: Development of patient-derived xenograft tumor model with organ-specific metastatic potential for evaluation of new therapeutics for hormone receptor-positive advanced breast cancer (2019) (0)
- Efficacy of Baseline Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) for Evaluation of Tumor Heterogeneity and Clinical Outcome in Advanced Breast Cancer (2022) (0)
- Abstract P6-13-05: Clinical-pathological features and treatment modalities associated with disease recurrence in DCIS and micro-invasive carcinoma (2015) (0)
- Abstract P4-05-18: Molecular portraits of metastatic breast cancer using tissue next-generation sequencing (2020) (0)
- Abstract P4-01-08: Characterization of circulating tumor free DNA (ctDNA) obtained from patients with metastatic breast carcinoma (MBC) undergoing systemic therapies using comprehensive genomic profiling (2019) (0)
- Abstract P4-06-03: Zinc Finger Nuclease Genome Engineering Reveal Multiple Functions of Secretory Leukocyte Peptidase Inhibitor in Regulating Pleuripotency of Cancer Stem Cells in Inflammatory Breast Cancer (2012) (0)
- ERBB2 amplifications and mutations in 109 advanced breast cancer patients by next-generation sequencing. (2020) (0)
- Breast conservation therapy in T4 locally advanced breast cancer: Effective local control with long-term survival (2004) (0)
- Brain Metastases in Women with Inflammatory Breast Cancer (IBC): Incidence, Treatment and Outcome. (2009) (0)
- Blood based cell biopsy for early detection of cancer (2016) (0)
- Abstract 1501: Exceptional response to anti HER-2 targeted therapy in patient with HER2/neu negative breast cancer with HER2/neu positive CTCs (2020) (0)
- Abstract P6-03-06: Circulating tumor DNA (ctDNA) for detection of molecular residual disease (MoRD) in breast cancer (2016) (0)
- Abstract P5-04-05: E-Cadherin is Required for In Vivo Growth of Inflammatory Breast Cancer: Importance of Mesenchymal-Epithelial Transition (MET) and Role of HIF1α (2012) (0)
- Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC (2022) (0)
- Abstract 3812: Innate immunity in inflammatory breast cancer (IBC) patients: Clues from HLA profiling (2010) (0)
- Abstract 3232: CEP-37440, a highly selective and potent dual inhibitor of ALK and FAK1 inhibits the proliferation of inflammatory breast cancer cells (2015) (0)
- Inflammatory Breast Cancer: It's Time to Take on the Challenges of a Complex Disease Model (2007) (0)
- IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure? (2020) (0)
- Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC) (2021) (0)
- Is sentinel lymph node biopsy (SLNB) routinely needed for breast cancers ≤5mm? (2014) (0)
- Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. (2023) (0)
- Abstract P5-13-29: Analytical and clinical validation of a ctDNA assay for detecting copy number loss and structural rearrangement variants contributing to homologous recombination and repair (HRR) deficiency (2022) (0)
- Running title : CTCs and staging in MBC (2018) (0)
- Abstract P6-12-01: Survival of women with inflammatory breast cancer: A large population based study (2013) (0)
- Abstract LB-314: Patients with inflammatory breast cancer have significant reductions in immune cells responsible for adaptive immunity (2010) (0)
- Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas (2016) (0)
- Abstract 1950: A novel ESR1 mutation assay for single circulating tumor cell by application of DEPArray࣪ System and Digital Droplet PCR (2022) (0)
- Abstract P2-06-18: Withdrawn (2019) (0)
- Abstract 4988: Clues for targeted therapies in inflammatory breast cancer (IBC) (2014) (0)
- Circulating cancer associated macrophage-like cells in the detection of invasive breast cancer. (2016) (0)
- Circulating tumor DNA (ctDNA) as a tool to help guide germline testing in patients with solid malignancies. (2021) (0)
- Abstract PS2-20: Prognostic value of baseline circulating tumor cells (CTCs) enumerations is for stage III and stage IV breast cancer (2021) (0)
- Experience of implementing a novel random sampling BICR audit for investigator (INV)-assessed progression-free survival (PFS) in the PALOMA-3 trial. (2017) (0)
- Clinico-pathological characteristics of breast cancer associated with thyroid disease (1999) (0)
- Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual? (2008) (0)
- Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients (2016) (0)
- Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival. (2010) (0)
- Predictive Biomarkers and Personalized Medicine Establishment and Validation of Circulating Tumor Cell – Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients (2013) (0)
- Abstract 2553: PSMA-specific, TGF-ß-insensitive CD8+T cells derived from metastatic castration resistant prostate cancer (mCRPC) patients induce apoptosis of PSMA positive prostate cancer (PCa) (2018) (0)
- Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC). (2018) (0)
- Functional (PET/CT) compared to conventional (mammography [M], sonography [US], MRI) imaging: Defining novel assessment modalities for inflammatory breast cancer (IBC) (2007) (0)
- 2010 The Influenceof ExtensiveIntraductalComponenton Outcomein Patientswith EarlyStageBreast Cancer Treated with Breast Conservation Therapy (2011) (0)
- Abstract 4918: Concordance of circulating tumor DNA (ctDNA) and next-generation sequencing (NGS) as molecular monitoring tools in metastatic breast cancer (MBC) (2015) (0)
- Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity (2022) (0)
- Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables (2014) (0)
- Abstract 224: Enrichment and isolation of uncontaminated breast cancer cells from human blood samples (2015) (0)
- Predictive value of CTCs biomarkers status in patients with metastatic breast cancer (MBC) receiving anti-HER2 therapy. (2014) (0)
- Abstract B141: Landscape of circulating tumor DNA (ctDNA) in refractory metastatic breast cancer:Real-timeevaluation of treatment-resistance (2019) (0)
- P1-02-07: Epithelial-Mesenchymal Transition Correlated with Serum Cytokine Profiling in Breast Cancer Patients. (2011) (0)
- Abstract LB117: Pilot study to identify live circulating tumor cells (CTCs) in metastatic breast cancer (MBC) by application of a novel microfluidic workflow system and flow cytometry (2022) (0)
- Breast cancer in young women: A single center study. (2014) (0)
- The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells (2016) (0)
- Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. (2015) (0)
- A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases. (2022) (0)
- Abstract P5-17-02: Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature (2019) (0)
- Predictive and Prognostic Value of Peripheral Blood Cytoketatin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients (2007) (0)
- Abstract P5-10-07: The LiquidBiopsy in metastatic breast cancer (MBC): A novel diagnostic platform for next generation sequencing (NGS) of circulating tumor cells (CTCs) (2015) (0)
- Prognostic Role of aMultigene ReverseTranscriptase-PCRAssay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant (2005) (0)
- Effect of Trastuzumab and Chemotherapy on Circulating Tumor Cells in Patients with Poor Prognosis Metastatic Breast Cancer. (2009) (0)
- Abstract 4887: DNA repair mutations are associated with mutational burden and T-cell activation signature in lung adenocarcinoma (2016) (0)
- Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (0)
- Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors (2023) (0)
- Abstract P5-15-03: Patient Characteristics and Clinical Outcome of Patients with Secondary Inflammatory Breast Cancer. M.D. Anderson Cancer Center, Retrospective Review (2010) (0)
- Abstract P3-01-05: Liquid biopsy methods and machine learning modeling to understand organ tropism and metastatization behavior of metastatic breast cancer (2020) (0)
- Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration (2018) (0)
- P4-20-02: Inflammatory Breast Cancer (IBC) in the National Comprehensive Cancer Network (NCCN): The Disease, the Recurrence Pattern and the Outcome. (2011) (0)
- Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer (2022) (0)
- Abstract P5-10-02: High serum levels of miR-19a are associated with poor outcome in metastatic inflammatory breast cancer (2012) (0)
- Abstract P6-05-07: Improving personalized management of primary breast cancer: Mammaprint® risk stratification and blueprint® molecular subtyping (2016) (0)
- Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis. (2009) (0)
- INOPERABLE INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER: WHAT’S NEW? (2021) (0)
- VOICES: HER2 Guideline Wonʼt Deter Genomic Testing (2014) (0)
- Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer (2021) (0)
- Ductal carcinoma in situ (DCIS): Ethnicity, clinical-pathologic features, and outcome. (2014) (0)
- B08 Impact of Concurrent STK11 Loss and c-MYC Amplification in Metastatic Non-Small Cell Lung Cancer (NSCLC) (2020) (0)
- all in one system for multiplex analysis of circulating tumor cells † (2016) (0)
- Abstract 304: Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer (2023) (0)
- CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome (2022) (0)
- Precision Oncology (2021) (0)
- Abstract P4-01-20: A novel microfluidic system for the detection, enumeration and molecular analysis of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) (2015) (0)
- Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. (2009) (0)
- Abstract P3-05-02: Detection of activating estrogen receptor 1 (ESR1) in circulating tumor DNA (ctDNA) in hormone-receptor positive metastatic breast cancer (MBC) (2016) (0)
- Circulating Tumor Cells in Individualizing Breast Cancer Therapy (2020) (0)
- Abstract P2-11-09: Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance (2020) (0)
- Abstract P4-01-07: Clinical relevance of CK+/CD45+, dual-positive circulating cells (DPCells) in patients with metastatic breast cancer (MBC) (2020) (0)
- Abstract P3-08-03: Establishment of patient-derived xenograft tumor models from breast cancer patients for quantitative elemental profiles and testing candidate therapies (2023) (0)
- Abstract PD9-07: Genomic landscape of metastatic breast cancer (MBC): Comprehensive cell-free DNA analysis from over 10,000 patients and comparison with primary breast cancer (2021) (0)
- Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC). (2019) (0)
- Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 (2017) (0)
- Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC). (2016) (0)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER 1 Advanced Breast Cancer (2021) (0)
- Abstract P1-03-06: Development of patient-derived xenograft tumor models and 3D spheroid culture from advanced hormone receptor-positive inflammatory breast cancer patients for evaluation of new therapeutics (2020) (0)
- Overexpression of Cyclooxygenase-2 in Celecoxib-Resistant Breast Cancer Cell Lines (2010) (0)
- Genomic Analysis of Advanced Breast Cancer Using Two Types of Next Generation Sequencing (2015) (0)
- Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers. (2018) (0)
- Using a Software Program to Support Shared Decision-Making about Participation in Breast Cancer Clinical Trials (2015) (0)
- Abstract P6-18-01: Novel genetic susceptibility loci for inflammatory breast cancer identified by whole exome sequencing (2016) (0)
- Inflammatory Mediators as Therapeutic Targets for Inflammatory Breast Cancer (2012) (0)
- Notch-1 expression is not related to the percentage of CD326+ cells in bone marrow aspirates of patients with primary breast cancer. (2009) (0)
- Circulating tumor cells (CTCs) in association to breast cancer subtypes and inflammatory pattern (2014) (0)
- Abstract P6-10-04: The Presence of Anaplastic Lymphoma Kinase Recapitulates Formation of Breast Tumor Emboli with Encircling Lymphovasculogenesis (2012) (0)
- Abstract 3281: Functional evaluation of response to targeted therapy in HER2 overexpressing inflammatory breast cancer (IBC) patients using positron emission mammography (PEM) (2010) (0)
- Abstract 384: Detection of circulating melanoma cells in paired arterial and venous specimens from uveal melanoma patients with hepatic metastatic (2015) (0)
- Inflammatory breast cancer and high-dose chemotherapy: back to the past. (2005) (0)
- Abstract PS2-15: The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer (2021) (0)
- Abstract P4-01-08: Anatomical staging and value of CTCs in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) (2020) (0)
- Abstract 6744: Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: A multi-institutional analysis of incidence and clinical outcomes (2023) (0)
- Abstract ES07-1: Inflammatory breast cancer: Diagnosis, treatment and biology (2013) (0)
- Abstract P4-01-11: Circulating tumor cells (CTCs) detect HER2+ status and phenotypic heterogeneity in metastatic breast cancer (MBC) (2015) (0)
- Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (2023) (0)
- Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog). (2018) (0)
- P3-03-02: Higher Expression Levels of Circulating miR-21, miR-19a and miR-10b Are Associated with High Risk Features in Breast Cancer. (2011) (0)
- Primary tumor size is associated with ALDHbrbreast cancer initiating stem cells in bone marrow aspirates of primary breast cancer patients. (2009) (0)
- Serum Tumor Markers and Circulating Tumor Cells (2008) (0)
- Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism (2022) (0)
- Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy. (2022) (0)
- 2–20 Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer (2007) (0)
- Abstract 4928: Clinical utility of circulating tumor DNA (ctDNA) in advanced and metastatic breast cancer (2015) (0)
- Inflammatory Breast Cancer: The Challenges Ahead (2009) (0)
- 322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3 (2020) (0)
- Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer. (2021) (0)
- Abstract 429: Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC) (2019) (0)
- Abstract P2-02-01: Stage IV stratification using circulating tumor cells (CTCs) enumeration modeling: A retrospective analysis of the MONARCH 2 study (2022) (0)
- Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. (2008) (0)
- Abstract P5-01-06: Cell-free DNA (cfDNA) analysis of ESR1-mutant advanced breast cancer (aBC): Impact of subsequent therapy on mutation persistence (2020) (0)
- A retrospective review of clinical and pathologic aspects of inflammatory breast cancer: Clues for risk-adapted monitoring and therapy. (2014) (0)
- Lapatinib-paclitaxel combo shows promise in IBC (2007) (0)
- P4-20-03: T-Cell Cytokine Production Related to Progression of Breast Cancer Patients. (2011) (0)
- Abstract P3-01-03: Circulating tumor cells (CTCs) with epithelial to mesenchymal transition (EMT) phenotype are associated with inferior outcome in primary breast cancer (2019) (0)
- Abstract LB-387: EZH2 knockdown suppresses the growth of human inflammatory breast cancer cells both in vitro and in vivo in xenograft models (2012) (0)
- Comprehensive Post-mastectomy Radiation Therapy (PMRT) in Inflammatory Breast Cancer (IBC) Patients with Limited M1 Disease (2011) (0)
- Abstract P3-01-10: Associations between plasma Interleukin 2 (IL-2) and HER2 expression in circulating tumor cell (CTC) and MYC alterations in circulation tumor DNA (ctDNA) open a new insight on immune microenvironment for patients with metastatic breast cancer (MBC) (2019) (0)
- Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)? (2019) (0)
- Abstract 1584: Comparison of circulating tumor cell (CTC) capture/identification methods and NanoString evaluation of gene expression in CTCs and cell-free circulating tumor mRNA (cctmRNA) in patients with metastatic lung cancer (2018) (0)
- Abstract OT3-01-01: A phase II study of PD-L1 and CTLA-4 inhibition and immunopharmcogenomics in metastatic breast cancer (2017) (0)
- Global evaluation of minimal residual disease in primary breast cancer patients (2008) (0)
- Abstract B42: Identification of molecular drivers in circulating tumor cell cluster formation and lung metastasis (2020) (0)
- Circulating tumor cells in newly diagnosed inflammatory breast cancer (2015) (0)
- Aldehyde Dehydrogenase1 Immunohistochemical Staining In Breast Cancer Tumor Cells Is Not A Surrogate For Circulating Or Disseminated Tumors Cells (2011) (0)
- Abstract 2788: Comprehensive high-depth target sequencing in circulating tumor DNAs of patients with inflammatory and non-inflammation breast cancers (2015) (0)
- CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer (2016) (0)
- Classifying circulating, mutation bearing tumor cells from breast cancer patients. (2013) (0)
- Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study (2005) (0)
- Detection, prevention et traitement du cancer du sein (2005) (0)
- Abstract 589: CCR5 upregulation in two subtypes of tumor associated circulating cells predict worse prognosis in metastatic breast cancer (2021) (0)
- Abstract P2-01-08: Esr1 Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer (2022) (0)
- Abstract PD10-01: PD10-01 Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach (2023) (0)
- Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa). (2019) (0)
- Abstract P3-03-03: Inflammatory breast cancer exhibits amplification and transcriptional activation of MYC in conjunction with NOTCH and TGFβ signaling (2020) (0)
- Clinical significance of time to relapse and the distinction between breast cancer recurrences and new primary tumors. (2011) (0)
- Abstract P5-03-11: Germline and somatic variants in patients with inflammatory breast cancer (IBC) detected using cell-free DNA (2020) (0)
- Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC) (2022) (0)
- Prevention strategies for breast cancer (2001) (0)
- P4-20-05: Inflammatory Breast Cancer: Comparison of Epidemiology, Biology, and Prognosis between Japan and the United States, a Hospital-Based Study. (2011) (0)
- Abstract 778: Identifying, subtyping and classifying tumor associated circulating endothelial cells in patients with solid tumors (2017) (0)
- Abstract P4-01-14: Association between interleukin 2 (IL-2) and circulating tumor DNA (ctDNA) is a novel biomarker for patients with metastatic breast cancer (BCa) after systemic therapies (2019) (0)
- Abstract P5-17-03: How is inflammatory breast cancer (IBC) different? Integration of clinico-pathological features and circulating tumor cells (CTCs)-based biomarkers for disease and prognostic assessment (2019) (0)
- Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer (0)
- Abstract 4847: Identifying molecular targets and mechanisms of treatment resistance in inflammatory breast cancer (IBC) using next-generation sequencing (NGS) and reverse-phase protein microarrays (RPMA) (2015) (0)
- Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12] (2020) (0)
- The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer. (2020) (0)
- Abstract P1-04-02: Correlation between blood markers of hemostasis and circulating tumor cells (CTCs) in early breast cancer patients (2013) (0)
- Abstract PS2-11: Ctc-her2+ a novel subset in stage IVaggressive: Molecular correlations, outcome and clinical characteristics in metastatic breast cancer (2021) (0)
- Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer (2022) (0)
- Abstract 767: Comparison of different methods for the detection of clusters of circulating tumor cells (2020) (0)
- 1–3 Health-Related Quality of Life Parameters as Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study (2005) (0)
- Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors 1 (2003) (0)
- Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer (2019) (0)
- Abstract PS2-08: Identification of incidental putative germline variants in circulating tumor DNA (2021) (0)
- Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network (NCCN): The Disease, The Recurrence Pattern, and The Outcome (2015) (0)
- Abstract OT3-26-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) (2023) (0)
- Abstract PS2-10: Circulating tumor DNA (ctDNA) as a diagnostic tool to identify putative germlineBRCAmutations (2021) (0)
- CD81 Facilitates Tumor Cell Clustering and Metastasis in Triple Negative Breast Cancer (2021) (0)
- CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer. (2022) (0)
- Immune cells from pleural fluids of patients with inflammatory breast cancer are immunocompetent. (2009) (0)
- Abstract P2-03-01: Identification of cancer stem cells (CD44+CD24−/lo) in bone marrow as a prognostic factor in early breast cancer patients (2012) (0)
- AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models (2014) (0)
- Abstract 586: Expression of CD68 on CKpos/CD45poscirculating cells in breast cancer patients: An additional hint supporting the fusion hybrid theory (2021) (0)
- Success of Preoperative Radiotherapy in Inflammatory Breast Cancer with Inadequate Response to Taxane-Based Chemotherapies (2020) (0)
- Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (2023) (0)
- Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (2019) (0)
- Abstract 172: Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing (2016) (0)
- 3–36 Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer Patients (2005) (0)
- Abstract HER2-08: HER2-08 Molecular characterization of HER-2 low patients identifies basal-enriched subset with poor clinical outcomes in real-world data (2023) (0)
- ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC). (2022) (0)
- Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer (2019) (0)
- Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date (2023) (0)
- Abstract 2603: Single cell RNA sequencing-based identification of molecular drivers in circulating tumor cell cluster formation and lung metastasis (2020) (0)
- A pilot study identifying cancer-associated macrophage-like cells in the blood of cancer patients. (2014) (0)
- Abstract PS2-33: Investigating oncogenic signaling pathways in inflammatory metastatic breast cancer (MBC) though circulating tumor DNA (ctDNA) next-generation sequencing (NGS) (2021) (0)
- Survival of women with in fl ammatory breast cancer : a large population-based study † (2014) (0)
- QS111. Correlation of COX-2 Expression With Triple Receptor Negative Status in Operable Human Breast Cancer (2008) (0)
- Abstract PD2-02: Longitudinal ctDNA sequencing using an expanded genomic panel in the PALOMA3 trial of palbociclib plus fulvestrant (2019) (0)
- Author response: Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer (2021) (0)
- ' s report Title : Gain in cellular organization of inflammatory breast cancer : A 3 D in vitro model that mimics the in vivo metastasis Version : 1 Date : 10 June 2009 (0)
- Immune phenotype of patients with stage IV metastatic inflammatory breast cancer (2020) (0)
- TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients (2014) (0)
- Abstract P2-14-05: Emerging molecular variants by circulating tumor DNA after immunotherapy in metastatic breast cancer (2022) (0)
- P4-09-08: Secretory Leukocyte Protease Inhibitor as a Differential Diagnostic Biomarker of Tumor Emboli in Inflammatory Breast Cancer. (2011) (0)
- Abstract P6-10-15: Targeting MARCKS in inflammatory breast cancer increased paclitaxel sensitivity (2023) (0)
- Abstract 5233: Concordance of genomic alterations by next generation sequencing (NGS) in tumor tissue vs. cell-free DNA (2016) (0)
- Genomic aberrations in advanced solid malignancies using next generation sequencing: A single institution experience. (2016) (0)
- Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies (2020) (0)
- Circulating tumor cells and risk of venous thromboembolism in metastatic breast cancer patients. (2016) (0)
- ' s response to reviews Title : Circulating Tumor Cells : A Tool Whose Time (2011) (0)
- Abstract P3-09-01: Higher Serum miR-21 Expression Correlates with Higher Levels of VEGF and bFGF in Patients with Metastatic Breast Cancer (2010) (0)
- Abstract PD04-03: Circulating Tumor Cells as Predictor of Metastatic Disease Spread in Patients with Breast Cancer (2010) (0)
- Abstract P6-04-13: Gene and microRNA Signatures of the Mesenchymal Epithelial Transition in Pre-Clinical Models of Inflammatory Breast Cancer (2010) (0)
- Abstract P2-08-04: Progressive metastatic breast cancer with no detectable circulating tumor DNA: Evaluating limitations of this highly sensitive tool (2022) (0)
- Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS) (2022) (0)
- A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone. (2014) (0)
- 218 Genomic analysis identifies novel drivers and targetable pathways in inflammatory breast cancer patient samples (2014) (0)
- Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC) (2022) (0)
- Understanding Metastasis in breast cancer to improve detection, monitoring and treatment. (2021) (0)
- The Influence of Extensive Intraductal Component on Outcome in Patients with Early Stage Breast Cancer Treated with Breast Conservation Therapy (2010) (0)
- Nobody Is Listening: Stories of Inflammatory Breast Cancer (2014) (0)
- Circulating tumor and endothelial cells as predictors of response in metastatic breast cancer (2007) (0)
- Circulating Tumor Cells and FDG-PET/CT for the Therapeutic Monitoring of Bone Metastases from Breast Cancer. (2009) (0)
- Abstract P6-12-14: Histone deacetylase inhibitor suberoylanilide hydroxamic acid targets breast cancer stem cells and inhibits metastasis (2013) (0)
- Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide (2023) (0)
- Abstract 1351: A novel application of DEPArrayTMNxT System to isolate circulating tumor cell (CTC)-clusters from patients with metastatic breast cancer (MBC) (2019) (0)
- Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China (2020) (0)
- Abstract P6-02-05: A novel culturing 3-D model to evaluate the role of tumor microenvironment in IBC. (2012) (0)
- P2-05-04: Mapping the Specific Gene Families Activated in the Lymphangiogenesis and Vasculogenic Mimicry Exhibited by Inflammatory Breast Cancer. (2011) (0)
- Circulating tumor cells (CTCs) in metastatic breast cancer: Ethnicity and disease subtypes. (2014) (0)
- Abstract PD6-5: Profiling of ESR1-mutated metastatic breast cancers by FoundationOne® allows a broad genomic understanding for potential clinical implications (2015) (0)
- of PSMA-targeted immunotherapy in prostate cancer…The Future is bright (2018) (0)
- Abstract PD1-02: Circulating tumor DNA (ctDNA): Areal-timeapplication of precision medicine to the management of metastatic breast cancer (MBC) (2017) (0)
- Thursday, 12 March 2009 11.00–12.30Session 4. Biology of breast cancer III: Stroma, angiogenesis and immunityS13 The biological information obtainable from circulating tumor cells (2009) (0)
- CD81 partners with CD44 in promoting exosome biogenesis, tumor cluster formation, and lung metastasis in triple negative breast cancer (2022) (0)
- Cancer Therapy : Preclinical Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer (2009) (0)
- 594 Dielectrophoresis (DEP) as sorting technology for microdiagnosis in breast cancer (2004) (0)
- Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer (2001) (0)
- Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis (2023) (0)
- 136P Paths of chromosomal instability and copy number alteration in circulating tumor cells of progressing early-stage breast cancer patients (2022) (0)
- Abstract P5-01-10: Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA (2020) (0)
- Platelets Lead Morphological, Phenotypic and Functional Changes in Tumor Cells. (2021) (0)
- Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome. (2020) (0)
- Abstract P2-26-06: Association between CK+/CD45+ circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) alterations in advanced breast cancer patients (2023) (0)
- p53 Mutation in Inflammatory Breast Cancer Cell Lines. (2009) (0)
- Abstract P3-01-05: Metabolomic analysis of breast cancer cell lines: Clues to the metabolic fingerprint of inflammatory breast cancer (2013) (0)
- Abstract P2-05-04: Comparative expression profiling of patient samples and preclinical models of inflammatory breast cancer reveals gene signatures of epithelial plasticity and suppression of TGFb signaling (2013) (0)
- Epstein-Barr virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells. (2009) (0)
- Abstract P2-01-05: Comprehensive analysis of genomic alterations in tumor tissue associated with presence of various subpopulations of circulating tumor cells (CTCs) in primary breast cancer (2018) (0)
- Abstract PS2-26: Evaluating the pathogenicity of emerging genomic aberrations detected by circulating tumor DNA over the course of metastatic breast cancer (2021) (0)
- Abstract P2-02-04: Distinct clinical and biological values of subpopulations of circulating tumor cells (CTCs) in primary breast cancer (2016) (0)
- Abstract P3-02-04: Dendritic Cells from Breast Cancer Patients with ≥5 CTCs Are Functionally Impaired (2010) (0)
- Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice (2021) (0)
- Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Massimo Cristofanilli?
Massimo Cristofanilli is affiliated with the following schools:
- University of Calgary
- Institute of Cancer Research
- MD Anderson Cancer Center
- KU Leuven
- Showa University
- University of California, San Diego
- Northwestern University
- University of Naples Federico II
- Baylor University
- Thomas Jefferson University
- University of Münster
- Seoul National University
- University of Milan
- University of Arizona
- University of Udine
- China Medical University
- Comenius University
- Okayama University
